Amsterdam-Duivendrecht, The Netherlands, August 17, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that it has obtained a debt facility of up to €15 million from Kreos Capital.
The loan consists of two tranches, with the first tranche of €10 million immediately drawn down and a second tranche of €5 million upon the company raising €20 million in additional funds. Kiadis Pharma will use the loan to advance the development of the Company’s ATIR products, for general corporate purposes and to repay the remaining €5.3 million of existing Dutch Government Loans. More… »
Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients suffering from blood cancers and inherited blood disorders, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nominate Dr. Otto Schwarz to be appointed as a new member of the Supervisory Board.
Dr. Otto Schwarz is a highly accomplished industry veteran, with significant operational and commercial leadership experience, including global launches of multiple major orphan and specialty care products. Most recently, Otto was Executive Vice-President, Chief Operating Officer and a member of the Actelion Executive Committee, up to the recent acquisition of Actelion by Johnson & Johnson. At Actelion, which he joined in 2008, Otto was responsible for global operations including marketing strategy & sales, medical affairs, manufacturing and supply chain, leading over 1300 people. Under Otto’s leadership, Actelion successfully launched the orphan products Opsumit, Uptravi and Veletri, growing total company sales to well over €2 billion. Prior to joining Actelion, he was Executive Vice-President Commercial Operations at Nycomed and an Executive Board Member at Altana Pharma. Prior to that he worked for almost 20 years at Schering-Plough and Eli Lilly in Austria, Switzerland, Canada, the US and Germany. Otto Schwarz is an Austrian citizen with a PhD in pharmaceutical chemistry from Vienna University. More… »
Amsterdam, The Netherlands, June 13, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Euronext Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces that it has raised €5 million in gross proceeds through a private placement (the “Transaction”) of new shares (the “New Shares”) completed prior to the open of the market today.
The Company has placed 746,269 New Shares with a small group of existing and new institutional investors at a price of €6.70 per New Share, which represents a 11% discount to the closing price of June 12, 2017. The New Shares represent 5.3% of the current number of outstanding shares (pre-Transaction) and will bring the total number of shares (post-Transaction) to 14,712,770. In addition, the investors have received 746,269 5-year warrants entitling them to subscribe for 746,269 new Company shares at a warrant exercise price of €7.70 (the exercise price being subject to adjustment in case of certain corporate and dilutive events).
The New Shares will be admitted to trading on Euronext Amsterdam and Euronext Brussels following their issuance, which is expected to take place on June 15, 2017.
Kiadis Pharma will use the net proceeds of the Transaction to advance the clinical development of the Company’s ATIR products and for general corporate purposes. More… »
Amsterdam, The Netherlands, April 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations for patients suffering from blood cancers and inherited blood disorders safer and more effective, today announces it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead product, ATIR101™. The Company is seeking marketing approval in the European Union for ATIR101™ as an adjunctive treatment in haematopoietic stem cell transplantation (HSCT) for malignant disease.
The filing is based on Kiadis Pharma’s existing clinical data and follows positive interactions with the EMA Rapporteur and Co-Rapporteur which indicated support for the filing using the Company’s single dose Phase II trial with ATIR101™ as the pivotal study. The Company submitted the application under the European Union’s centralized procedure, which permits the agency to issue a single marketing authorization that is valid across all EU countries. More… »
~ Regulatory approval received from the national authority in Belgium to start pivotal Phase III trial with ATIR101™ and from the national authority in Germany to start the Phase I/II trial with ATIR201™ ~
Amsterdam, The Netherlands, April 3, 2017, – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that it has obtained regulatory approval from the national authority in Belgium (the FAGG, the Federal Agency for Medicines and Health Products) to start its randomized, controlled, transatlantic Phase III clinical trial with ATIR101™ for acute leukemia (CR-AIR-009) in Belgium. In addition, the Company has received regulatory approval from the national authority in Germany (the PEI, the Paul-Ehrlich-Institute) to start its Phase I/II clinical trial with ATIR201™ for thalassemia (CR-BD-001). This follows after the previous Company announcement in February 2017 that the Phase III trial with ATIR101™ has been initiated following regulatory approval from the national authority in Canada, and from the previous Company announcement at the end of 2016 that it had initiated the Phase I/II trial with ATIR201™ after having obtained regulatory approval from the national authority in the United Kingdom.